General Experimental Procedure. MagnaBind TM Streptavidin coated beads in phosphate-buffered saline (PBS) pH 7.5 containing 0.1% BSA, EDTA and sodium azide, were supplied by Thermo Scientific. Beads were saved at 4°C and opened just prior to use. The binding capacity of beads is 8 nmol of biotin/mL of beads. The 5' biotinylated, native and mutated anti-ATP aptamers and complementary sequences of these aptamers in desalted form were supplied by IDT and were used as received. Adenosine-triphosphate disodium salt hydrate (ATP), Cytidine 5'-triphosphate disodium salt (CTP), Guanosine 5' triphosphate sodium salt hydrate (GTP), Glucose oxidase from Aspergillus niger Type VI-A, Flavin adenine dinucleotide disodium salt hydrate (FAD), 4-Aminoantipyrine, 3, 5-dichloro-2-hydroxybenzesulfonate, sodium phosphate monobasic, and glucose were purchased from Sigma Aldrich. Sodium phosphate dibasic (EMD), magnesium chloride (Acros Organic) and Ultrapure glycerol (Invitrogen) were used as received. Sodium chloride, magnesium chloride, ammonium sulfate and Tris hydrochloride were purchased from Fischer Scientific. The anti-ATP aptamer (ATP-A) binding buffer composition was adapted from a previously reported procedure (Tris 20 mM, NaCl 300 mM , MgCl 2 5 mM, pH 7.54)(1).
A typical glucose assay was carried out by mixing the following reagents to a total volume of 1 mL in a 1.5 mL disposable cuvette. Diluted and pre-mixed solutions of 4-aminoantipyrine and 3, 5-dichloro-2-hydroxybenzensulfonate in 0.1M phosphate buffer pH 6.2 (500 µL) was transferred to a cuvette. Solutions of glucose (550 mM, 50 µL) and POD (60U/mL, 50 µL) were added to the cuvette followed by the addition of water (390 µL). Reactivated apo-Gox (10 µL) was added to cuvette and intial rate of change in absorbance was measured every 15seconds for 2 mins.
FAD displacement experiment
The experimental details of dose dependent FAD displacement by ATP are described herein. MagnaBind beads (250 µL, 2 nmol biotin) were transferred to six different tubes respectively. The beads were washed with 0.1M phosphate buffer pH 7.4 (200 µL × 2) followed by 200 µL binding buffer (Tris 20 mM, NaCl 300 mM , MgCl 2 5 mM, pH 7.5). After the washing step, 5'-Biotinylated ATP-A (50 µM, 200 µL) was added to the beads contained within the six reaction tubes respectively. The control tubes contained only 200 µL of binding buffer. The reaction tubes were incubated at 50 °C for 30 min followed by 2 h at room temperature. Excess 5'-biotinylated ATP-A was separated from the beads by using a magnet to separate the bead and solution slurry. The amount of ATP-A present on the beads was calculated by subtracting ATP-A concentration before and after incubation with the beads by measuring absorbance at 260 nm. On average, 5.7 nmol ATP-A was calculated to be bound on the beads under the conditions mentioned in these experments. Beads containing bound ATP-A in the reaction tubes were washed with binding buffer (100 µL, 2X). The remaining trace buffer was completely removed from the beads using the magnet. Solutions of FAD (50 µL, 1.2×10 -6 M) were added to each tube containing ATP-A conjugated to MagnaBind. The mixture in the tubes were incubated at 4 °C overnight. The excess unbound FAD supernatant was removed from the beads using the magnet and saved in reaction tubes labeled as No ATPA-control, F-1, F-2, F-3, F-4 and F-5 (see main text Figure 2B ). The beads were washed with binding buffer (50 µL). Solutions of ATP (50 µL) at concentrations in the range of 10 to 500 µM were added to the tubes containing the ATP-A/FAD (and controls) bead complex. The control tubes only received the 25µM ATP (50 µL) solution. The tubes were gently vortexed at 4 °C for 8h. The respective reaction supernatants were removed from the beads and collected in separate tubes labeled appropriately for each of the concentrations. Solutions (20 µL) of the supernatant containing displaced FAD were transferred to 0.5 mL reaction tubes respectively. Aliquots of apo-GOx (20 µL, 2 mg/mL) were added to each individual tube containing the displaced (and control) FAD solutions. All the tubes were incubated at room temperature and gently vortexed for 3 h. Simultaneously, solutions of FAD 1.2 × 10 -6 M in binding buffer (positive control) and an aliquot of only binding buffer (negative control) were also incubated with apo-GOx (2mg/mL) and vortexed. The previously described Glucose assay was carried out with 10 µL of the reactivated apo-GOx using freshly prepared reagents.
For the selectivity experiments, GTP and CTP were used to displace FAD in addition to ATP. The remaining procedures were similar to those described in the previous section.
ATP-A was mutated (G to A) at positions G22, G9 and both G9/22 to determine the putative binding site for FAD. In this particular experiment, mutated 5'-biotinylated ATP-A sequences were conjugated with MagnaBind by adapting experimental details used in the FAD displacement experiments. In addition to ATP-A, G22 mutated ATP-A (G22M), G9 mutated ATP-A (G9M) and G9/22 mutated ATPA (G9/22M) were also conjugated to different aliquots of MagnaBind beads respectively. The complementary sequence of each of the respective aptamers (60 µM, 50 µL) was added to the reaction tubes. FAD displaced by complementary sequences was used for reactivation of apo-GOx as previously described.
Total amount of FAD displaced by ATP
The experimental procedures for ATP-A bead binding and FAD complexation were described in the previous section. After removal of the excess FAD supernatant, the ATP-A/FAD complexed beads were washed with 100μl binding buffer. ATP (250 and 500 μM) was added to different tubes containing the complex under similar conditions. The released FAD was used to reactivate apo-GOx and determine percent release. With concentrations of 250µM ATP, ~96% of the ATP-A bound FAD is released (Total ATP-A bound FAD is determined from the subtraction of FS-1 and FS-2 from FS-Ctrl respectively, Figure S1 ). Addition of 500 μM ATP showed a further 2% increase in FAD release, and signifies the upper limit of this assay.
Figure S1: The data shows the leftover FAD (FS-1 and FS-2) from the initial ATP-A/FAD complex. This data can be subtracted from the FS-control peak in order to gauge the maximum bound FAD. The ATP 250 and ATP 500 data show the initial velocity measured from the FAD that is released from the ATP-A/FAD complex in the presence of 250μM and 500μM ATP respectively. The data set also includes the positive and negative controls showing the maximum FAD related signal (if 100% of the FAD added was bound to ATP-A) and the residual signals from apo-GOx.
Stability of ATPA-FAD complex
Magna beads (250 µL) were transferred in 5 tubes. All the steps were similar as in previous experiments as mentioned above. After removal of supernatant from FAD -ATPA magnabeads, the beads were washed with 100 µL binding buffer. Then, binding buffer (50 µL) was added in each tubes and vortexed gently for 1 to 4 days at 4 °C. The glucose assay was carried out for supernatant of tube 1 after day 1 whereas tube 2, 3, 4 were measured after 2, 3, 4 days respectively. Figure S2 shown below is the initial rate versus buffer supernatants of tubes from the different days. The fourth day sample shows less than 15 % FAD dissociated from FAD-ATPA complex in buffer when compared to total amount of FAD bound to the ATP-A. There is minimal difference between the FAD that is released from day 1 to day 4 of the study. Figure S2 : Tubes T-1 to T-4 contained ATP-A bound to FAD. This data (T-1 to T-4) shows the initial velocity measured from the FAD that is released from the ATP-A/FAD complex in the absence of ATP after excess FAD is removed. T-1 was measured after day 1, T-2 after day 2, T-3 after day 3 and T-4 after day 4. The control bead represents the maximum amount of reactivation from FAD in the absence of aptamer. The positive control aliquot does not contain aptamer or beads and thus represents the maximum reactivation of enzyme with the total FAD that was initially added to the ATP-A. 
Isothermal Titration Calorimetry (ITC)
Anti-ATP aptamer solutions (ATP-A) (400 µL, 50 µM) were prepared in binding buffer (Tris 20 mM, NaCl 300 mM, MgCl 2 5 mM, pH 7.4). ATP 200 µL (700 µM) and FAD 200 µL (900 µM) solutions were also prepared in binding buffer. All the samples and buffers for the washing syringe were sonicated for 15 mins at RTP. A solution of ATPA (or mutated aptamers) (400 µL) was loaded in a deep well plate assigned as the target while ATP or FAD solutions were loaded in a deep well plate assigned as the ligand, for syringe injection. The first injection was set at 0.1 µL and the remaining 18 injections were set at 2 µL for total injections of 19. The ATP or FAD was injected to the cell containing the ATP-A (or mutated aptamer) solution at 25 °C. Upon completion of the injections, the data was processed using MicroCal Auto itc Origin Software. The corresponding thermodynamics parameters are shown in Table  S1 . 
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